Gold prices steady ahead of Fed decision, Trump’s tariff deadline
Kathryn Romano, Chief Accounting Officer at Krystal Biotech Inc. (NASDAQ:KRYS), a $5 billion market cap biotechnology company with impressive 93% gross margins and "GREAT" financial health according to InvestingPro, recently executed a series of stock transactions involving the company’s common stock. According to a recent SEC filing, Romano sold 750 shares on February 27, 2025, at a price of $175.22 per share, amounting to a total of $131,415. This transaction was conducted under a pre-established Rule 10b5-1 trading plan.
Additionally, Romano engaged in several other transactions involving the company’s stock. On February 26, 2025, she surrendered 2,268 shares valued at $176.39 each for tax withholding purposes. On February 28, 2025, Romano also surrendered 2,315 shares and 3,471 shares at $179.25 each, also for tax withholding. The stock, which has demonstrated remarkable revenue growth of 473% over the last twelve months, is currently trading near its InvestingPro Fair Value.
In terms of stock acquisitions, Romano exercised performance stock units and options, acquiring a total of 12,500 shares without any immediate financial outlay. These transactions reflect Romano’s ongoing involvement with Krystal Biotech’s equity compensation plans. With a strong current ratio of 7.28, the company maintains robust liquidity. For deeper insights into KRYS’s valuation and 12 additional ProTips, visit InvestingPro.
In other recent news, Krystal Biotech announced its 2024 financial results, revealing earnings per share (EPS) of $1.52 for the fourth quarter and $3.00 for the full year. These figures were slightly below some analysts’ expectations, which anticipated $1.81 for the quarter and $3.31 for the year. The company reported total revenue from its product VYJUVEK at $91.1 million for the fourth quarter and $290.5 million for the year, which also fell short of projections. Despite the revenue miss, Krystal Biotech’s financial position remained strong with $749.6 million in cash and investments at year-end. H.C. Wainwright maintained a Buy rating for Krystal Biotech, setting a price target of $221, reflecting confidence in the company’s growth prospects. VYJUVEK’s success was highlighted, with over 510 reimbursement approvals and plans for launches in Europe and Japan. Additionally, Krystal Biotech is advancing its pipeline programs, including preparations for the European and Japanese market entries of VYJUVEK. The company also expects a decision from Japan’s Pharmaceuticals and Medical (TASE:BLWV) Devices Agency in the second half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.